Lundbeckfonden Ventures nyheder

Lund, Sweden, 08.00 CET, 20 February 2018 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform today announces the publication of its Q4 and Year-End Report – January – December 2017. 2017 net sales increased by...
Cambridge, Mass. (Business Wire) February 13, 2018 – Imara, Inc. today announced it has dosed the first patient in its Phase 2a clinical trial, evaluating the safety, pharmacokinetics and pharmacodynamics of escalating doses of IMR-687 in adult patients with sickle cell disease (SCD). IMR-687 is a highly potent and selective inhibitor of phosphodiesterase-9 (PDE9i) in blood...
Lund, Sweden, 08.00 CET, 6 February 2018 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform, will publish its Year-end Report for January-December 2017 on Tuesday 20 February 2018 at 08.00am CET. The Company will...
Lund, Sweden, 18:00 CET 1 February 2018 – BONESUPPORT HOLDING AB’s subsidiary BONESUPPORT AB has repaid the remaining debt under the loan facility from Kreos Capital V (UK) Ltd. The original loan agreement, which was signed in September 2016 included two tranches, one of EUR 13.4 million and one of EUR 8.9 million. BONESUPPORT has...
Lund, Sweden, 18:00 CET 31 January 2018 – During January, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 31 January 2018, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 50,368,766. About BONESUPPORT™ BONESUPPORT is an innovative and...
Lund, Sweden 08.30 CET, 23 January 2018 – BONESUPPORT (Nasdaq Stockholm: BONEX), an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform, announces that the Board of Directors has appointed Emil Billbäck as the new CEO of...
Lund, Sweden, 08.00 CET, 22 January 2018 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique platform  announces that a paper “Gelatin- hydroxyapatite-calcium sulphate based biomaterial for long term sustained delivery of bone morphogenic protein-2 and zoledronic...
SAN DIEGO – January 8, 2018 – Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, with a near-term focus on deadly fungal pathogens, today announced that Alan Fuhrman has been appointed as Chief Financial Officer of Amplyx. The Company also announced today that Ciara Kennedy, Ph.D., Chief Executive Officer of Amplyx, will present...
Palma, Spain, and San Diego, USA, January 8, 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced the appointment of Cris Calsada as Chief Financial Officer. Ms. Calsada joins Sanifit with over 20 years of corporate finance and executive experience in the life sciences and technology industries....
1 2 3 41

Lundbeckfonden Ventures

Nyheder

BONESUPPORT™ HOLDING AB (Publ) – Q4 and 2017 Year-End Report – January – December
20. februar 2018
Imara Doses First Patient in Phase 2a Clinical Trial of IMR-687 for Sickle Cell Disease
14. februar 2018
BONESUPPORT HOLDING AB – Year-end Report January-December 2017 – invitation to conference call and webcast
6. februar 2018